Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
NCT04261686 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.
Conditions Studied
Interventions
- DEVICE Covera Vascular Covered Stent
Study Locations (11)
Minnesota
- University of Minnesota Medical Center — Minneapolis
- Minnesota Vascular and Surgery Center — New Brighton
Texas
- Dallas Renal Group — Dallas
- San Antonio Kidney and Disease Access Center — San Antonio
Arizona
- Arizona Kidney Disease and Hypertension Center Medical Research Services — Phoenix
Connecticut
- Yale University — New Haven
Illinois
- Chicago Access Care — Westmont
Massachusetts
- Kidney Care & Transplant Services of New England — West Springfield
Michigan
- Michigan Vascular Center — Flint
North Carolina
- North Carolina Nephrology — Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2025-09-16 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04261686
The ClinicalTrials.gov registry entry for NCT04261686 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 46 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Arteriovenous Fistula appearing as the primary indexed condition, and to 1 intervention — of which Covera Vascular Covered Stent is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04261686 reports 11 study locations spanning 9 distinct geographic areas — top geographies include Minnesota, Texas, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04261686 about?
NCT04261686 is a clinical study titled "Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft". The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.
What is the current status of trial NCT04261686?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2020-07-03. Estimated completion is 2025-09-16.
What conditions does trial NCT04261686 study?
This clinical trial studies the following conditions: Arteriovenous Fistula. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04261686?
The interventions under investigation include: Covera Vascular Covered Stent (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04261686?
This trial is sponsored by C. R. Bard, which has 46 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04261686 being conducted?
This trial has 11 study locations across Arizona, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.